#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Obliterative bronchiolitis Arginase deficiency Colon cancer Hyperphagia Neurotrophic keratopathy Chronic kidney disease Chronic hepatitis B Tourette's disorder Oropharyngeal squamous cell carcinoma Proteus syndrome Leukoencephalopathy Dermatitis Mantle cell lymphoma recurrent Autoimmune hepatitis Andersen-Tawil syndrome More trials…

    Learn about Rare Diseases

    Adrenogenital syndrome – Life with Disease Gastrointestinal stromal tumour – Life with Disease Hepatic angiosarcoma – Treatment Primary immunodeficiency syndrome – Life with Disease Congenital generalised lipodystrophy – Trials in Disease Cholangitis sclerosing Pemphigus Angiosarcoma recurrent Malignant fibrous histiocytoma – Basic Information Activated PI3 kinase delta syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rimegepant Sorafenib Tosilate Desflurane Wt1 Mrna Dc Dipyridamole Ulotaront Istradefylline Cytisine Dl-Alpha-Tocopherol Daptomycin Perindopril Arginine Miglustat TTX-381 Calcium ALE.P03 Etifoxine Hydrochloride IMELASOMERAN Aldesleukin Sodium Sulfate Anhydrous Vortioxetine Hydrobromide More therapies…

    Learn about Your Condition

    White matter lesion Rheumatoid arthritis Choroidal neovascularisation Ejection fraction normal Left ventricular dysfunction Anal cancer stage II Parkinson's disease Knee arthroplasty Mucous membrane pemphigoid Overweight Osteogenesis imperfecta Metastatic neoplasm Erythema Congenital ureteric anomaly Neonatal respiratory failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study of Olaparib for Patients with Advanced Cancer Having HRRm or HRD Mutations

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Olaparib
    Denmark France Ireland Italy Romania Spain

  • Study on the Safety and Effectiveness of ALLO-501A and ALLO-647 for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Allo-501A
    • Allo-647
    • Famotidine
    Italy Spain

  • Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Allo-501A
    • Allo-647
    • Famotidine
    Austria Belgium Germany

  • Study on Ganaxolone for Patients with Refractory Status Epilepticus

    Not recruiting

    3 1
    Investigated Diseases:
    • Status epilepticus
    Investigated Drugs:
    • Ganaxolone
    Austria Belgium Croatia Czechia Denmark Finland +8

  • Study on the Effects of Leriglitazone for Adult Men with Cerebral Adrenoleukodystrophy

    Not recruiting

    3 1
    Investigated Diseases:
    • Adrenoleukodystrophy
    Investigated Drugs:
    • Leriglitazone
    France Germany Spain

  • Study on the Effects of Maridebart Cafraglutide for Adults with Type 2 Diabetes

    Not recruiting

    2 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Greece Hungary Italy Poland Romania +2
Previous Page
1 … 1,643 1,644 1,645 1,646
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!